Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant.
The kinetics of the gB-specific and neutralizing antibody responses to human cytomegalovirus (HCMV) were analyzed in 26 allogeneic stem-cell transplant recipients who either did (n = 20) or did not (n = 6) develop asymptomatic HCMV active infection during the study period. Antibody response profiles varied widely among individuals in both groups, irrespective of whether HCMV active infection did or did not occur. Development of HCMV active infection was not preceded by a decline in functional serum antibody levels. Neither the absence nor the presence of HCMV active infection correlated with either high or low serum levels of gB-specific and neutralizing antibodies, respectively. In most patients, episodes of HCMV replication were not followed by a marked increment in functional serum antibody titers. Therefore, resolution of an ongoing HCMV active infection was not associated with a vigorous antibody response to viral replication. In addition, this study supports previous data indicating that passive transfer of human immunoglobulins may result in an increment in gB-specific and neutralizing serum antibody levels, the magnitude of which varies among recipients; however, both patients with and without measurable increments in serum antibody levels developed HCMV active infections with comparable frequency.
Muñoz
I
I
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
Gutiérrez
A
A
Gimeno
C
C
Farga
A
A
Alberola
J
J
Solano
C
C
Prósper
F
F
García-Conde
J
J
Navarro
D
D
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000276:immunology*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014184:Transplantation, Homologous; D014759:Viral Envelope Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D007136:Immunoglobulins; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus